Chief Financial Officer · KalVista Pharmaceuticals, Inc. · KalVista Pharmaceuticals, Inc. — Restricted Stock Unit
Side
M
Value
—
Shares
6,250
Price
—
Executed
Apr 16, 2026
Disclosed
Apr 20, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Apr 16 executedApr 20, 2026 disclosed
KALV · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Option exercise — administrative, little informational value
Relative size+5 / 25
No reported dollar value · 7.1% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
1 prior trade recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
KalVista Pharmaceuticals, Inc. — Restricted Stock Unit
Ticker
KALV
Shares
6,250
Price per share
$0
Execution date (reported)
Apr 16, 2026
Owned after transaction
93.8K shares
Days from execution to publication
4
What this establishes
Piekos Brian filed this Form 4 reporting a option exercise of KALV on Apr 16, 2026. It became public on Apr 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Piekos Briancik:0001815308
Issuer
KalVista Pharmaceuticals, Inc.cik:0001348911
Revision history · 0
No field has changed since this record was first ingested.
